Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

被引：214

作者：

Chen, Jiang ^{[1
]}

Jin, Renan ^{[1
]}

Zhao, Jie ^{[1
]}

Liu, Jinghua ^{[1
]}

Ying, Hanning ^{[1
]}

Yan, Han ^{[1
]}

Zhou, Senjun ^{[1
]}

Liang, Yuelong ^{[1
]}

Huang, Diyu ^{[1
]}

Liang, Xiao ^{[1
]}

Yu, Hong ^{[1
]}

Lin, Hui ^{[1
]}

Cai, Xiujun ^{[1
]}

机构：

[1] Zhejiang Univ, Dept Gen Surg, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China

来源：

CANCER LETTERS | 2015年 / 367卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG SIGNALING PATHWAY; ALPHA-B-CRYSTALLIN; LIVER-CANCER CELLS; PHASE-III; PROMOTES METASTASIS; DEPENDENT MECHANISM; PLUS SORAFENIB; BREAST-CANCER; UP-REGULATION;

D O I：

10.1016/j.canlet.2015.06.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 11

页数：11

共 168 条

[11] Inflammation and Liver Cancer New Molecular Links [J].

Berasain, C. ;

Castillo, J. ;

Perugorria, M. J. ;

Latasa, M. U. ;

Prieto, J. ;

Avila, M. A. .

STEROID ENZYMES AND CANCER, 2009, 1155 :206-221

[12] SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24-Phenotype [J].

Bhat-Nakshatri, Poornima ;

Appaiah, Hitesh ;

Ballas, Christopher ;

Pick-Franke, Patricia ;

Goulet, Robert, Jr. ;

Badve, Sunil ;

Srour, Edward F. ;

Nakshatri, Harikrishna .

BMC CANCER, 2010, 10

[13] Cancer stem cells and EMT in carcinoma [J].

Biddle, Adrian ;

Mackenzie, Ian C. .

CANCER AND METASTASIS REVIEWS, 2012, 31 (1-2) :285-293

[14]

Bielecka Zofia F, 2014, Curr Signal Transduct Ther, V8, P218

[15] Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells [J].

Blivet-Van Eggelpoel, Marie-Jose ;

Chettouh, Hamza ;

Fartoux, Laetitia ;

Aoudjehane, Lynda ;

Barbu, Veronique ;

Rey, Colette ;

Priam, Sabrina ;

Housset, Chantal ;

Rosmorduc, Olivier ;

Desbois-Mouthon, Christele .

JOURNAL OF HEPATOLOGY, 2012, 57 (01) :108-115

[16]

Bolondi L, 2008, 2008 GASTR CANC S OR, P25

[17] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].

Bonnet, D ;

Dick, JE .

NATURE MEDICINE, 1997, 3 (07) :730-737

[18] Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study [J].

Brandi, Giovanni ;

de Rosa, Francesco ;

Agostini, Valentina ;

di Girolamo, Stefania ;

Andreone, Pietro ;

Bolondi, Luigi ;

Serra, Carla ;

Sama, Claudia ;

Golfieri, Rita ;

Gramenzi, Annagiulia ;

Cucchetti, Alessandro ;

Pinna, Antonio Daniele ;

Trevisani, Franco ;

Biasco, Guido .

ONCOLOGIST, 2013, 18 (12) :1256-1257

[19] Management of Hepatocellular Carcinoma: An Update [J].

Bruix, Jordi ;

Sherman, Morris .

HEPATOLOGY, 2011, 53 (03) :1020-1022

[20] ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition [J].

Buonato, Janine M. ;

Lazzara, Matthew J. .

CANCER RESEARCH, 2014, 74 (01) :309-319

← 1 2 3 4 5 6 7 8 9 10 →